ASH 2023 - CLL

Long-Term Outcomes of Ibrutinib Therapy in CLL

ASH 2023 - CLL

Long-term follow-up data of a phase 2 study confirmed the extended prognosis of ibrutinib-treated patients with CLL, particularly those with TP53 alterations. Read More ›

Extended Follow-up of ALPINE Study Confirmed Superior PFS Benefit of Zanubrutinib Versus Ibrutinib in R/R CLL/SLL

ASH 2023 - CLL

Longer follow-up data of the randomized, phase 3 ALPINE study confirmed PFS benefit and more favorable cardiac safety profile of zanubrutinib compared to ibrutinib therapy in patients with R/R CLL/SLL, with emergence of no new safety signals. Read More ›

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab in Relapsed/Refractory CLL

ASH 2023 - CLL

Results of the phase 2 CLL2-BAAG trial showed that MRD-guided triple combination therapy of acalabrutinib, venetoclax and obinutuzumab yielded better efficacy outcomes, deeper remission, and achievement of uMRD in patients with R/R CLL. Read More ›

Phase 1/2 Study Data of Combination Sonrotoclax (BGB-11417) Plus Zanubrutinib in Treatment-Naïve CLL/SLL

ASH 2023 - CLL

Data from an ongoing, first-in-human phase 1/2 study suggests that combination sonrotoclax (160 mg and 320 mg) plus zanubrutinib therapy was well tolerated and showed encouraging anti-leukemic activity in patients with treatment-naive CLL/SLL. Read More ›

ASH 2023 - CLL

Page 2 of 2